The stage is set for the diffusion of positron emission tomography (PET) in oncology

Medical Journal of Australia

Volumn 171, Issue 10, 1999, Pages 527-528

  Morris, John G ^a  

^a Australian Nucl Med PET Consult ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE;

AUSTRALIA; BIOCHEMISTRY; CANCER; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; HEALTH CARE FACILITY; ONCOLOGY; REVIEW;

EID: 0033571764     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1999.tb123786.x     Document Type: Review

References (12)

1. Sokoloff L, Reivich M, Kennedy C, et al. The [14C] deoxyglucose method of local cerebral glucose utilisation: Theory, procedure, and normal values in the conscious and anaethestised albino rat. J Neurochem 1977; 28: 897-916.
2. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): non-toxic tracer for rapid tumor detection. J Nucl Med 1980; 21: 670-675.
3. Proceedings of the 46th Annual Meeting of the Society of Nuclear Medicine, Los Angeles, California, 1999. J Nucl Med 1999; 40 (Suppl): 5.
4. Commonwealth Department of Health and Aged Care (Diagnostics and Technology Branch). Review of positron emission tomography (PET). Canberra: The Department, July 1999.
5. Valk PE. Effect of FDG-PET on patient management and cost. Handout book. Reston, Va (USA): Society of Nuclear Medicine, 1999: 200-204.
6. Hicks RJ, Binns DS, Fawcett ME, et al. Positron emission tomography (PET): experience with a large-field-of-view three-dimensional PET scanner. Med J Aust 1999; 171: 529-532.
7. Valk PE, Pounds TR, Tesar TD, et al. Cost-effectiveness of PET in clinical oncology. Nucl Med Biol 1996; 23: 737-743.
8. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective evaluation of positron emission tomography in lung nodules. J Clin Oncol 1998; 16: 1075-1084.
9. Gambhir SS, Hoh CK, et al. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996; 37: 1428-1436.
10. HCFA expands Medicare coverage of PET. J Nucl Med 1999; 50: 23N.
11. Bailey DL, Miller MP, Spinks TJ, et al. Experience with fully 3D PET and implications for future high-resolution 3D tomographs. Phys Med Biol 1998; 43: 777-786.
12. Hutton B. Emerging clinical applications of quantitative emission computed tomography. In: Pham B, Braun M, Maeder AJ, Eckert MP, editors. New approaches in medical image analysis, 1999. Proceedings of SPIE (International Society of Optical Engineering) 1999; 3747: 57-76. (ISBN 0-8194-3229-6.)